Supanji Supanji
Department Of Ophthalmology, Faculty Of Medicine, Public Health, And Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Ophthalmology Clinic, Dr. Sardjito General Hospital, Yogyakarta, Indonesia

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

Age and gender distribution of pterygium cases from the pterygium surgery social service program Supanji Supanji; Tania Purbonegoro; Anindita Dianratri; Krisna Dwi Purnomo Jati; Agung Saputro; Aloysius Angga Wibowo; Suhardjo Suhardjo
Journal of Community Empowerment for Health Vol 4, No 2 (2021)
Publisher : Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jcoemph.62285

Abstract

Pterygium is an eye condition that causes abnormal growth of fibrous tissue on the sclera. Pterygium could cause vision impairment when it reaches the area that blocks the pupil. Though the cause is still inconclusive, pterygium is associated with older age and male gender. The incidence of pterygium in Yogyakarta remains relatively unreported due to little documentation. This study aimed to report findings from the Pterygium Surgery Social Service Program, focusing on the age and sex distribution from several communities in Gunung Kidul, Yogyakarta. This study was a descriptive cross-sectional study. Study subjects were pterygium patients from the social service program organized by the Department of Ophthalmology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, in October 2018 – March 2020. There were 227 patients consisted of 151 female patients (66.5%) and 76 male patients (33.5%). There were 22 patients (9.7%) who had grade I pterygium, 137 patients (60.4%) had grade II pterygium, 45 patients (19.8%) diagnosed as having third-grade pterygium, and 23 patients (10.1%) had grade IV pterygium. On average, female patients made a higher proportion of those having pterygium in all grades. The majority of patients in all age groups fell into second-grade pterygium, except for those aged >70 years old who had a higher number of those in the grade III category. In conclusion, female subjects made a higher proportion than males in all pterygium grades, and those aged 70 years and older had a more severe stage.
Surgical Technique of Late Spontaneous IOL-Capsular Bag Complex Dislocation with Low Corneal Endothelial Cell Density: A Case Report Firman Setya Wardhana; Dhimas Hari Sakti; Supanji Supanji; Muhammad Bayu Sasongko; Tri Wahyu Widayanti; Angela Nurini Agni
International Journal of Retina Vol 2 No 1 (2019): International Journal of Retina (IJRetina) - INAVRS
Publisher : Indonesian Vitreoretinal Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35479/ijretina.2019.vol002.iss001.54

Abstract

Introduction: IOL-capsular bag complex dislocation is a rare but serious complication of phacoemulsification surgery. Technique to repair this complication should be based on various clinical parameters including quality of corneal endothelial cells and the type of dislocated IOL. Case Presentation: We present a case of a 67-year-old male with left eye spontaneous one-piece foldable IOL-capsular bag complex dislocation to vitreous cavity 4 years after phacoemulsification surgery. Visual acuity of the left eye was 1/60, pupil was round with 3 mm diameter and IOP was 15 mmHg. Noncontact specular microscopy examination showed that the corneal endothelial cell density was 1100 cells/mm2. It was managed with 23-gauge posterior vitrectomy, IOL evacuation to anterior chamber, releasing the capsular bag and repositioning the IOL into posterior chamber by sutured scleral fixation. Result: Follow-up at 6thmonth, best corrected visual acuity of the left eye achieved 6/6, IOL at central position and the last corneal endothelial cell density was 1076 cells/mm2. Conclusions: Late spontaneous IOL-capsular bag complex dislocation with low corneal endothelial cell density can be safely managed with proper surgical technique. Vitrectomy and sutured scleral fixation of the previously dislocated IOL were effective in managing such case. Longer follow-up should be done to assure the stability of IOL position and the quality of corneal endothelial cells.
CENTRAL MACULAR THICKNESS REDUCTION AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB COMPARED TO INTRAVITREAL KETOROLAC IN NAIVE DIABETIC MACULAR EDEMA Supanji Supanji; Angela Nurini Agni
International Journal of Retina Vol 5 No 2 (2022): International Journal of Retina (IJRetina) - INAVRS
Publisher : Indonesian Vitreoretinal Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35479/ijretina.2022.vol005.iss002.203

Abstract

Introduction: Diabetic macular edema (DME) is a debilitating complication of the diabetic eye. Vascular Endothelial Growth Factor (VEGF) was found to be responsible for this disease entity, and anti-VEGF remains the main treatment of DME. Inflammatory processes occur in diabetic eye, with some researchers postulates the role of them in the making of DME. This study’s objective is to search for anti-VEGF alternative using Non-Steroid Anti-Inflammatory Drugs (NSAID), ketorolac tromethamine. Methods: We conducted a double blind, randomized clinical trial in DME patients using intravitreal injection of bevacizumab and ketorolac. Central macular thickness (CMT) was assessed pre-treatment and one-month post-treatment. Best Corrected Visual Acuity (BCVA) and Intraocular Pressure (IOP) were also assessed. Wilcoxon tests were performed to evaluate changes in CMT, visual acuity, and IOP. Result: We enrolled 50 treatment-naïve DME patients from March 2020 to March 2021. Twenty-five patients were allocated for each group. There is a statistically significant difference in CMT at one-month follow-up between the two groups (p:0.001) and a markedly reduced CMT between the groups (p:0.001), with the reduction higher in bevacizumab group. BCVA changes significantly in bevacizumab group (p:0.01), but there is no statistically significant difference between the two groups (p:0.07). There’s a marked difference of IOP in 1 hour after injection in both groups, with higher transient IOP elevation in ketorolac group (p:0.02), but there is no marked difference in one-month follow-up (p:>0.05). The perceived pain right after intravitreal injection is not different between bevacizumab and ketorolac group. Conclusion: Intravitreal injection of ketorolac found to be inferior compared to bevacizumab in reducing CMT of DME. Meanwhile, there’s no differences in visual acuity, intraocular pressure (one-month follow-up) and pain after injection between two groups.